Chinese Biopharma Stocks Rally as U.S. Signals Openness to Drug Licensing

‘High tide’ of China biotech deals seen as US curb fears fade: analysts

Stocks jump on reports Washington will allow most licensing deals under ‘substantially softer stance’ than had been feared, analysts say.

Chinese biopharma stocks rally as U.S. signals openness to drug licensing

Chinese biopharma stocks jump as the U.S. may allow most drug licensing deals with China.

Chinese biopharma stocks jump as U.S. weighs keeping door open to drug deals

Chinese biopharma stocks rose on Monday after a report that the U.S. may continue to allow most drug licensing deals with Chinese firms.

Chinese Biotech Deals Poised for Growth Amid Easing US Restrictions

China biotech deals are poised for growth as Washington shifts away from imposing broad restrictions, analysts say. This positive outlook comes after Beijing unveiled an ambitious five-year plan for the healthcare sector. Nomura's head of China healthcare research Jialin Zhang predicts that out-licensing deals between China and the US will benefit from this favorable environment. According to Reuters, the US Treasury Department is working on inv…